ITHS Tools
Connect with Us
Need Help? Have a Question?
 

Latest News

Latino communities are growing rapidly in the WWAMI (Washington, Wyoming, Alaska, Montana, and Idaho) region that the Institute of Translational Health Sciences (ITHS) serves. Also growing is the need for high-quality, community-engaged health research to promote the health of these diverse communities, which face significant...

The PENUT (Preterm Epo Neuroprotection) trial is a new study being led by University of Washington researchers who are assessing whether erythropoietin (Epo) can provide neurological protection for infants who are born extremely prematurely. This study is seeking a treatment for the approximately 50,000 infants...

Dr. Aaron Kusano, a resident in the University of Washington Department of Radiation Oncology, has research interests that he admits fall a bit outside the conventional realm of radiation oncology. He has examined the burnout amongst academic chairs of radiation oncology departments in the past. He...

The Institute of Translational Health Sciences (ITHS) hosted 14 researchers from five different Chinese hospitals on Tuesday, January 14, 2014. The delegation, which was organized and led by Dr. Tim Shi of GlobalMD, was interested in learning more about translational research, the ITHS Clinical Research...

If a trauma patient has uncontrolled bleeding, the therapeutic priority is to stop the bleeding as quickly as possible. However, a patient may have hard-to-diagnose, life-threatening condition called trauma-induced coagulopathy (TIC) that can increase blood loss. A team led by Nathan Sniadecki in the UW Department...

The Institute of Translational Health Sciences has reopened its Gene and Cell Therapy Lab. As a biologic manufacturing facility designed to support Phase I/II clinical trials, the lab recently redesigned its operations to address the unique requirements for novel gene and cell therapy products. Located within...

In the world of drug development, researchers may experience many false starts and tests before a compound successfully makes it through clinical trials and enters the market.  In fact, approximately 1 in 12 treatments ever make it to patients. What happens to promising molecular compounds...

If you've been the recipient of ITHS resources, please mention us in your publication, press release, or presentation. Just copy and paste our pre-written text into your document. We’ve included the basic guidelines below. Thank you for your cooperation in acknowledging our support of your work. Example...